Sorriso’s mission is to harness the power of oral biologic therapies that can be delivered directly to the site of disease, improving efficacy, safety and convenience for patients suffering from chronic illnesses.
Investors 1
Mentions in press and media 3
| Date | Title | Description |
| 03.09.2024 | Sorriso Pharmaceuticals Completes Enrollment in Phase 1b Clinical Trial of Patients with Ulcerative Colitis | Innovative Oral Dual-Acting Biologic Targeting TNFα and IL-23 p19 in Ulcerative Colitis SALT LAKE CITY, UT, UNITED STATES, September 3, 2024 /EINPresswire.com/ -- Sorriso Pharmaceuticals, a biopharmaceutical company developing novel oral an... |
| 17.05.2024 | Sorriso Pharmaceuticals Announces First Patients Dosed in Phase 1b Clinical Trial for Patients with Ulcerative Colitis | Study to Evaluate SOR102, a Novel Oral Dual-Acting Antibody Targeting TNF⍺ and IL-23 (p19) for Inflammatory Bowel Disease SALT LAKE CITY, UT, UNITED STATES, May 17, 2024 /EINPresswire.com/ -- Sorriso Pharmaceuticals, a biopharmaceutical com... |
| 22.12.2021 | Sorriso Pharmaceuticals Launches with $31 Million to Develop Novel Class of Orally Delivered Cytokine Antibodies to Treat Inflammatory Conditions | SALT LAKE CITY, Dec. 22, 2021 /PRNewswire/ -- Sorriso Pharmaceuticals, a company focused on transforming anti-inflammatory antibody therapy, today announced the company has closed on a $31 million Series A financing. The round was co-led by... |
Reviews 0
